Business
Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership
Partnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the
About this update from Guardant Health, Inc.
[{"type":"text","content":"\n\nPartnership marks the first introduction of Shield™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the Philippines\n\n\n\nEligible Manulife customers in Hong Kong, Singapore and the Philippines will gain access to the Shield MCD test beginning in April 2026\n\n\n\n PALO ALTO, Calif. & HONG KONG--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of the Shield™ multi-cancer detection (MCD) laboratory developed test (LDT) in multiple markets in Asia. The Shield MCD test is a methylation-based blood test for the detection of multiple cancer types including bladder, colorectal, breast, prostate, esophageal, gastric, liver, lung, ovarian and pancreas cancer in individuals aged 45 or older who are at typical average risk for cancer.\n\n\nThe partnership with Manulife marks a first-of-its kind collaboration with a major insurer in Asia to expand access to early cancer detection in the region by offering innovative technologies like Guardant’s Shield MCD test to address real, unmet health needs. As part of the partnership, eligible Manulife customers in Hong Kong, Singapore and the Philippines will gain access to the Shield MCD test beginning in April 2026. Manulife is a large insurer in Asia serving customers across life, health, retirement and other wealth products and services.\n\n\n“The introduction of our Shield MCD test in Asia marks a critical milestone in our mission to transform early detection and expand commercial access globally,” said AmirAli Talasaz, Guardant Health co-CEO. “We built our Shield technology from the ground-up nearly 10 years ago with a vision to address the most common cancers where early detection is a critical component to survivorship. Shield MCD has the potential to significantly increase screening participation in Asia with the promise of detecting multiple cancers at an early stage with just a blood draw.”\n\n\nCancer remains one of the leading causes of death in Asia. With just a blood draw, the Shield MCD test screens for 10 of the most common cancers, many of which carry high mortality rates in the region.\n\n\n“By being the first insurer in Asia to offer the Shield MCD test, we’re empowering our customers with a credible and valued service that encourages proactive health management...